FDA Brief

Warning letters Drugs

FDA warning letter to

Medical Products Laboratories, Inc.

High riskIssued Apr 9Posted Apr 14Center for Drug Evaluation and Research (CDER)

Medical Products Laboratories was cited for manufacturing failures and selling unapproved prescription skin drugs.

What happened

FDA inspected the Philadelphia drug manufacturing facility from September 29 to October 16, 2025. Investigators found non-sterile drug products with gross microbiological contamination, inadequate process validation, and inadequate investigations and stability data. The letter also cites labeling for prescription skin products and says they are unapproved new drugs because no approved applications are in effect.

What FDA found

  1. The firm did not have adequate written procedures to prevent harmful microorganisms in non-sterile drugs and used an unvalidated treatment to try to reduce contamination.

    21 CFR 211.113(a)
  2. The firm did not adequately validate its manufacturing processes and relied on a study from a different facility.

    21 CFR 211.100(a)
  3. The firm did not thoroughly investigate failing microbiological results, out-of-specification stability results, or complaints, and invalidated failures without adequate justification.

    21 CFR 211.192
  4. The firm's stability program did not support the labeled storage conditions and expiration dates.

    21 CFR 211.166(a)
  5. The firm marketed prescription skin products as new drugs without FDA-approved applications.

    FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)

What FDA wants

FDA asks the firm to provide comprehensive independent assessments, risk assessments, investigations, validation and stability remediation plans, and to engage a qualified consultant to audit its drug manufacturing quality system. The provided letter text does not state a response deadline.

Who should pay attention

  • brands that buy finished prescription skin drugs from contract manufacturers
  • pharmacies and patients using sodium sulfacetamide/sulfur or hydroquinone products
  • quality teams overseeing contract manufacturing and supplier quality agreements

This is a summary. Read the original letter on fda.gov.

Medical Products Laboratories, Inc.'s FDA history

Recalls in the last 12 months

Dec 3, 2025 Class II Medical Products Laboratories, Inc.
Drug
Walgreens Saline Nasal Spray WITH XYLITOL, 1.5 oz (45mL) bottle, DISTRIBUTED BY: WALGREEN CO., 200 WILMOT RD., DEERFIELD, IL 60015, NDC 0363-3114-01
Microbial contamination of a non-sterile product - microorganism found to be pseudomonas lactis

Full company page

Similar letters to other companies

  1. CNC Noodle Corporation

    FDA warned CNC Noodle Corporation that its Hayward, California noodle plant had insanitary conditions, no pathogen or allergen controls, and mislabeled products.

    High risk
  2. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  3. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  4. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk